Introduction

Dry eye disease (DED) represents one of the most common and clinically challenging ocular complications in patients with diabetes mellitus. Epidemiological data indicate that between 15% and 50% of individuals with diabetes will experience clinically significant dry eye during their lifetime, with prevalence increasing in parallel with disease duration and glycemic burden. The pathophysiology is complex and multifactorial, involving reduced tear production from lacrimal gland dysfunction, accelerated tear evaporation due to meibomian gland abnormalities, and fundamental alterations in tear film composition that collectively destabilize the ocular surface. Artificial tears remain the first-line intervention for symptomatic relief, yet the specific role of sodium in these formulations is frequently underestimated despite its direct influence on tear film osmolality, corneal epithelial barrier integrity, and the inflammatory cascade that perpetuates ocular surface disease. A precise understanding of how sodium concentration interacts with the uniquely vulnerable diabetic ocular surface can empower clinicians and patients to make more informed treatment selections, leading to improved symptom control and reduced risk of long-term corneal complications. This article examines the physiological basis for sodium-balanced lubricating formulations, the distinctive challenges that diabetes imposes on tear film homeostasis, and practical, evidence-based strategies for optimizing artificial tear selection in this growing patient population.

The Diabetes-Dry Eye Connection

Chronic hyperglycemia initiates a cascade of metabolic, neuropathic, and microvascular changes that compromise every structural and functional layer of the tear film. The relationship between diabetes and dry eye is bidirectional and self-reinforcing: diabetes damages the structures that produce and maintain tears, while the resulting ocular surface inflammation further impairs corneal health and glycemic control through stress-mediated pathways. The prevalence of DED in diabetic cohorts rises consistently with hemoglobin A1c levels, duration of diagnosed diabetes, and the presence of peripheral neuropathy. Left untreated, dry eye in the diabetic patient significantly increases the risk of corneal epithelial defects, infectious keratitis, slow-healing ulcers, and permanent visual impairment.

How Diabetes Damages the Ocular Surface

Multiple interconnected mechanisms drive the destruction of tear film stability in diabetes:

  • Autonomic neuropathy of the lacrimal gland: Damage to parasympathetic nerve fibers that innervate the lacrimal gland markedly reduces both basal and reflex aqueous tear secretion. This volumetric deficit concentrates all tear solutes, including sodium, and initiates a cycle of increasing osmolality and epithelial stress.
  • Meibomian gland dysfunction (MGD): Elevated blood glucose alters the lipid composition of meibum, increasing its melting point and viscosity. These changes promote ductal obstruction, gland atrophy, and dropout. Without a stable lipid layer, tear evaporation accelerates dramatically, further concentrating tear solutes and raising osmolality.
  • Corneal nerve degeneration: Diabetic peripheral neuropathy reduces corneal nerve density and sensitivity. This loss blunts the blink reflex, diminishes neurotrophic support for epithelial cell proliferation and migration, and decreases reflex tearing. The result is a cornea that is both dry and poorly equipped to repair itself.
  • Goblet cell loss and mucin deficiency: Hyperglycemia reduces the density of conjunctival goblet cells and decreases secretion of MUC5AC, the primary gel-forming mucin. The tear film becomes less viscous and less capable of retaining water on the ocular surface, accelerating breakup time and promoting dry spot formation.
  • Hyperosmolar tear film: The combined effects of reduced tear volume, accelerated evaporation, and altered electrolyte handling produce a sustained hyperosmolar environment, typically exceeding 310 mOsm/L. This hyperosmolarity is the central driver of ocular surface inflammation in dry eye disease.
  • Inflammatory amplification: Hyperglycemia directly upregulates pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and matrix metalloproteinases (MMPs) within the conjunctiva, lacrimal gland, and meibomian glands. This inflammatory milieu further damages tear-secreting tissues and sensitizes the ocular surface to osmotic stress.

These interconnected pathways produce a chronic, often moderate-to-severe dry eye that responds poorly to interventions that fail to address the underlying osmotic and inflammatory disturbances.

The Hyperosmolarity Cycle

Tear film hyperosmolarity is not merely a consequence of diabetes-related dry eye but is itself a pathogenic driver that perpetuates and worsens the condition. When tear osmolality rises above the normal physiological range, water exits corneal and conjunctival epithelial cells by osmosis. Cellular shrinkage triggers activation of stress-activated protein kinases, including p38 MAPK and JNK, which initiate a pro-inflammatory gene expression program. This program includes release of IL-1β, TNF-α, and MMP-9, which degrade the epithelial basement membrane, promote apoptosis, and reduce goblet cell density. The loss of goblet cells further destabilizes the tear film, worsening evaporation and raising osmolality even higher. Breaking this vicious cycle requires interventions that normalize tear osmolality while suppressing inflammation. Sodium concentration is the primary determinant of tear osmolality, making it a critical therapeutic target.

The Science of Sodium and Tears

Normal human tears have an osmolality of approximately 302 mOsm/L, with sodium as the dominant cation at concentrations ranging from 130 to 145 mmol/L. This osmolality is maintained within a narrow physiological range because it directly controls corneal epithelial cell volume, membrane integrity, metabolic function, and signaling pathways. Even small deviations from this range trigger compensatory and stress responses that can become maladaptive when sustained.

Osmolality and Corneal Epithelial Health

When tear osmolality exceeds 310 mOsm/L, corneal epithelial cells undergo immediate osmotic water loss. Cell shrinkage activates the regulatory volume increase response, which involves uptake of ions and organic osmolytes. However, if hyperosmolar stress persists, cells undergo apoptosis through both intrinsic mitochondrial pathways and extrinsic death receptor pathways. The corneal epithelium in diabetic patients is particularly vulnerable because baseline hyperglycemia already induces endoplasmic reticulum stress and oxidative damage, lowering the threshold for osmotic injury. Even brief, intermittent exposure to hyperosmolar tears causes measurable epithelial cell desquamation and barrier disruption. Artificial tears that restore physiological osmolality offer direct protection against this cascade, reducing inflammation and supporting epithelial healing.

Sodium's Role Beyond Tonicity

Beyond its role as the primary driver of osmolality, sodium interacts directly with charged mucins to form a hydrated gel that coats and protects the corneal epithelium. This mucin-sodium gel reduces surface tension, improves tear film spreading, and provides a reservoir of moisture that resists evaporation. In diabetic dry eye, where mucin production is reduced by goblet cell loss, maintaining an appropriate sodium concentration becomes even more important to support the spreading and stability of the aqueous layer. Potassium and bicarbonate also contribute to the electrolyte balance of tears, but sodium is present in the highest concentration and is the principal determinant of tonicity. Formulations that match or closely approximate the sodium content of natural tears therefore provide the most physiological support for the compromised diabetic ocular surface.

Formulation Considerations for Artificial Tears

Artificial tears vary widely in their sodium content, osmolality, viscosity, preservative status, and additional ingredients. These differences translate directly into clinical performance, particularly for patients with diabetes who have specific vulnerabilities and higher baseline osmolality. Understanding the formulation landscape is essential for rational product selection.

Osmolality Classes and Their Clinical Fit

  • Isotonic formulations: With an osmolality near 300 mOsm/L, isotonic drops (such as many products in the Systane and Refresh families) match normal tear osmolality. These are appropriate for patients with mild, episodic dry eye or those who have not yet developed significant baseline hyperosmolarity. However, for diabetic patients with established hyperosmolar tears (≥310 mOsm/L), isotonic drops provide only transient relief because they do not dilute the concentrated tear film sufficiently to break the inflammatory cycle.
  • Hypotonic formulations: These drops have an osmolality in the range of 230 to 280 mOsm/L (e.g., TheraTears and certain sodium hyaluronate products). The mildly hypotonic design draws water into the tear film by osmosis, effectively diluting concentrated solutes and reducing tonicity toward normal levels. For moderate-to-severe diabetic dry eye with documented hyperosmolarity, a hypotonic formulation may provide superior symptom relief and faster improvement in objective signs such as corneal staining and tear breakup time. However, the sodium concentration should remain above 120 mmol/L to avoid disrupting mucin hydration and to maintain epithelial cell volume regulation.
  • Hypertonic formulations: Products with osmolality above 350 mOsm/L (such as Muro 128) are designed to draw fluid out of the cornea and are indicated for corneal edema, typically in conditions such as Fuchs endothelial dystrophy or after cataract surgery. These drops are generally contraindicated in diabetic dry eye because they worsen preexisting hyperosmolarity and can accelerate epithelial damage.

Selecting the Right Sodium Concentration

The ideal artificial tear for a patient with diabetes should meet several specific criteria:

  • Preservative-free: This is a non-negotiable requirement for diabetic patients who use artificial tears more than four times daily or on a long-term basis. Benzalkonium chloride (BAK), the most common preservative in multi-dose bottles, causes dose-dependent corneal epithelial toxicity, reduces goblet cell density, destabilizes the tear film, and can exacerbate neurotrophic keratopathy. Diabetic corneas with preexisting nerve damage and impaired healing are especially vulnerable. Single-dose vials or preservative-free multi-dose bottles (which use mechanical or chemical preservative-free delivery systems) are strongly preferred.
  • Osmolality in the 280-310 mOsm/L range: A mildly hypotonic formulation (approximately 280-295 mOsm/L) offers the ideal balance between dilution of hyperosmolar tears and maintenance of physiological tonicity to support epithelial function. Formulations that fall below 275 mOsm/L may cause epithelial edema in some patients and should be used with caution.
  • Sodium concentration between 130 and 150 mmol/L: This range matches or slightly undercuts natural tear sodium levels, providing appropriate tonicity without disrupting electrolyte-dependent mucin function.
  • Supplementary lubricants and viscosity agents: Ingredients such as carboxymethylcellulose (CMC), sodium hyaluronate, hydroxypropyl methylcellulose, or glycerin improve retention time on the ocular surface, extend the interval between applications, and provide mechanical protection to the corneal epithelium. Sodium hyaluronate is particularly advantageous because the molecule itself contributes a mild hypotonic effect while providing excellent water retention and viscoelastic properties.
  • Balanced electrolyte composition: Some advanced formulations include potassium, bicarbonate, and calcium in proportions that match natural tear fluid. These additional electrolytes support epithelial cell metabolism, buffer pH, and stabilize the tear film.

The Preservative Problem in Diabetic Eyes

Benzalkonium chloride (BAK) is a quaternary ammonium compound that acts as a detergent, disrupting microbial cell membranes. Unfortunately, it also disrupts the lipid layer of the tear film and damages corneal epithelial cells. In diabetic eyes, the toxic effects of BAK are amplified. Studies have demonstrated that diabetic corneas exposed to BAK show greater epithelial cell apoptosis, reduced nerve density, delayed wound closure, and increased inflammatory cytokine release compared to nondiabetic controls. The Tear Film & Ocular Surface Society (TFOS) Dry Eye Workshop II guidelines specifically advise against the use of preserved artificial tears in patients with systemic diseases that affect the ocular surface, including diabetes. The TFOS DEWS II report provides comprehensive recommendations for tailoring tear substitutes to patient-specific comorbidities, emphasizing the importance of preservative-free formulations in vulnerable populations.

Clinical Evidence Supporting Sodium-Balanced Formulations

A growing body of clinical evidence supports the superiority of sodium-balanced, preservative-free artificial tears in diabetic patients with dry eye disease. These studies demonstrate that addressing the osmotic component of dry eye yields measurable improvements in both subjective symptoms and objective clinical signs.

Key Clinical Findings

A 2020 randomized controlled trial published in Cornea evaluated the efficacy of hypotonic sodium hyaluronate (0.15%) compared with isotonic saline in 60 diabetic patients with moderate dry eye. After four weeks of treatment four times daily, the sodium hyaluronate group demonstrated a 40% reduction in corneal fluorescein staining scores, a significant improvement in tear breakup time (from 4.2 to 7.1 seconds), and a clinically meaningful reduction in Ocular Surface Disease Index (OSDI) scores. The saline group showed minimal change across all endpoints, underscoring that the hypotonic and viscoelastic properties of the active formulation were responsible for the therapeutic benefit.

Another randomized trial compared a formulation containing sodium carboxymethylcellulose (0.5%) plus glycerin against a polyethylene glycol-based artificial tear in 80 diabetic patients with dry eye. The sodium-CMC/glycerin combination produced significantly greater improvements in tear osmolarity (reduction from 318 to 301 mOsm/L) and tear breakup time (increase from 3.8 to 6.5 seconds). These results highlight the synergistic role of appropriate sodium content and high-retention lubricant bases in stabilizing the tear film.

A systematic review published in the International Journal of Molecular Sciences (2021) analyzed data from 14 clinical trials involving diabetic patients with dry eye. The review concluded that restoring tear film osmolality to physiological levels is a primary therapeutic target in this population and that artificial tears with appropriate sodium content directly interrupt the hyperosmolar-inflammatory cycle that perpetuates ocular surface disease. Access the full systematic review here.

“For diabetic patients, restoration of tear film osmolality to physiological levels is a primary therapeutic target. Drops with appropriate sodium content directly address the hyperosmolar inflammatory cycle.” — International Journal of Molecular Sciences, 2021

Building a Comprehensive Treatment Plan

While sodium-balanced artificial tears represent a cornerstone of therapy, optimal management of diabetic dry eye requires a multifaceted approach that addresses the underlying drivers of disease and incorporates adjunctive strategies to support tear film stability and ocular surface health.

Glycemic Optimization

Rigorous glycemic control remains the most fundamental intervention for preventing and managing diabetic dry eye. Maintaining HbA1c below 7% (or an individualized target based on age, comorbidities, and hypoglycemia risk) slows the progression of lacrimal gland damage, meibomian gland dropout, and corneal nerve degeneration. Tight glycemic control also reduces the concentration of inflammatory cytokines in tears and improves the metabolic environment for epithelial healing. Every dry eye management plan for a diabetic patient should include a discussion of glycemic targets and coordination with the patient’s primary care provider or endocrinologist.

Lid Hygiene and Warm Compresses

Meibomian gland dysfunction is present in a majority of diabetic patients with dry eye and is a primary driver of evaporative dry eye. Daily warm compresses applied at 40–45°C for 10–15 minutes liquefy thickened meibum and improve gland expression. Gentle lid massage following the compress helps express obstructed secretions. For patients with more advanced MGD, in-office procedures such as meibomian gland expression or intense pulsed light (IPL) therapy may be indicated to restore gland function and reduce tear evaporation.

Nutritional Support

Omega-3 fatty acid supplementation, with a target intake of at least 1000 mg of combined eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) daily, has demonstrated benefit in reducing ocular surface inflammation and improving meibomian gland function. Some studies also suggest that vitamins A, C, D, and E may support tear film stability and epithelial health, although the evidence is less robust. Patients should be advised to obtain these nutrients through diet or high-quality supplements after discussing with their physician, particularly if they are taking anticoagulant medications.

Environmental Modifications

Environmental factors that accelerate tear evaporation should be identified and mitigated. Using a humidifier in dry indoor environments, avoiding direct airflow from heating vents, fans, or air conditioning, and wearing moisture-chamber glasses or wrap-around sunglasses outdoors can significantly reduce evaporative stress. Patients who spend extended periods using digital devices should be counseled on the importance of frequent breaks and conscious blinking exercises, such as the 20-20-20 rule (every 20 minutes, look at something 20 feet away for 20 seconds).

When to Escalate Care

If dry eye symptoms persist despite consistent use of preservative-free, sodium-balanced artificial tears applied four to six times daily, comprehensive evaluation by an eye care professional with dry eye expertise is warranted. Objective diagnostic testing, including tear osmolarity measurement, non-invasive tear breakup time, meibography, and corneal staining with fluorescein and lissamine green, can identify the predominant mechanism and guide targeted therapy. The American Diabetes Association’s Standards of Medical Care in Diabetes recommend annual comprehensive eye examinations for all patients with diabetes, with specific attention to the ocular surface in those reporting dry eye symptoms.

For patients who fail to achieve adequate control with artificial tears and lifestyle measures, advanced therapeutic options include punctal occlusion (plugs or cautery) to conserve natural tears, topical anti-inflammatory agents such as cyclosporine A (0.05% or 0.1%) or lifitegrast (5%), and autologous serum tears, which provide growth factors and anti-inflammatory mediators that support corneal healing. In select cases, oral secretagogues or scleral contact lenses may offer additional benefit. The goal of escalation is to break the inflammatory cycle and create an environment in which the patient’s own tear film and the adjunctive lubricants can function optimally.

Conclusion

Sodium is far more than a simple electrolyte in artificial tear formulations. It is a critical regulator of tear film osmolality, corneal epithelial cell volume and viability, mucin hydration and spreading, and the inflammatory signaling cascade that drives and perpetuates dry eye disease. For diabetic patients, whose baseline tear film is already hyperosmolar, inflammatory, and structurally compromised, selecting an artificial tear with an appropriate sodium concentration represents a targeted therapeutic intervention rather than a mere palliative measure. The ideal formulation for diabetic dry eye is preservative-free, mildly hypotonic (osmolality 280–310 mOsm/L), with a sodium concentration of 130–150 mmol/L, and enriched with a high-retention lubricant base such as sodium hyaluronate or carboxymethylcellulose. By matching the formulation to the specific pathophysiology of diabetic dry eye, clinicians can break the hyperosmolar-inflammatory cycle, provide meaningful symptom relief, and reduce the risk of corneal complications. Ongoing research into next-generation formulations that combine optimized sodium content with anti-inflammatory agents, osmoprotectants, and mucin-stabilizing compounds holds promise for further improving outcomes in this growing and clinically challenging patient population.